Treatment with oncogenic tyrosine kinase inhibitors has led to a dramatic change in the overall survival rates of patients with chronic myeloid leukemia (CML). 1 Dasatinib is an oral tyrosine kinase inhibitor of bcr-abl, Src, c-kit and the platelet-derived growth factor receptor-alpha and -beta (PDGFR-a, PDGFR-b). Like imatinib, it has been shown to be safe and effective in patients with CML. 2 Both drugs are capable of prompting interaction with different enzyme cascades but their mechanism of action and side effects are still under investigation. For example, c-kit, PDGFR-a and PDGFR-b are also important signal transduction modulators in testis organogenesis, Leydig's cell differentiation and recruitment, spermatogenesis and steroidogenesis, whereas Src supports spermatogenesis and fertility by acting as a signal transductor for testosterone action in Sertoli cells. 3, 4 The authors of two recent reports document several cases of gynecomastia in male patients treated with imatinib for CML or gastrointestinal stromal tumor and hypothesize a mechanism by which the drug reduces testosterone production through the block of PDGFR and c-kit in the testis. 5, 6 We describe gynecomastia and its management in a male patient after treatment with dasatinib for CML.
In April 2007, a 70-year-old man was referred to our center for leukocytosis (white blood cells (WBC) 17.7 Â 10 9 /l, hemoglobin (HGB) 13.5 g per 100 ml, platelets (PLT) 230 Â 10 9 /l) and mild splenomegaly. After a bone marrow aspirate, he was diagnosed with CML in the chronic phase. The karyotype 46,XY,t(9;22) (q34;q11) was found in 85% of the metaphases. In May 2007, he started treatment with 400 mg oral imatinib daily. Complete hematologic response was achieved after 24 days of therapy. Immediately before undergoing bcr-abl molecular evaluation, planned at the third month of therapy, the patient developed skin toxicity (Grade 3 Common Toxicity Criteria) with generalized erythema and widespread maculopapular eruption associated with severe pruritus. Imatinib was stopped for 3 weeks with some dermatologic improvement. Only a few days after reintroducing oral imatinib (200 mg daily) in combination with steroids, the patient experienced recrudescence of the skin disorders. Imatinib treatment was then definitively discontinued due to nonhematologic intolerance to the drug.
In September, blood tests showed leukocytosis (WBC 14.8 Â 10 9 /l, HGB 13.7 g per 100 ml, PLT 240 Â 10 9 /l) and cytogenetic evaluation of bone marrow revealed 80% of metaphases harbouring the 46,XY,t(9;22)(q34;q11) translocation. Considering the patient's intolerance to imatinib, treatment was started with oral dasatinib, 100 mg daily. Complete hematologic response was achieved after 21 days of therapy. Two months later, physical examination revealed bilateral gynecomastia, with enlargement of soft and elastic tissue concentric to the nipple area ( Figure 1) . Moreover, the patient complained of severe pain in the nipple areas (odynomastia). A mammography showed bilateral fibroglandular enlargement, particularly in the left mammary gland. The full spectrum of steroid and stimulating hormones was evaluated and a retrospective analysis on serum stored before dasatinib therapy was performed ( Table 1 ). The patient had not taken any other medication potentially capable of influencing hormone levels.
At this point, dasatinib was combined with tamoxifen, a selective estrogen-receptor modulator, at an oral dose of 20 mg daily. Within 1 month of treatment, there was significant regression of gynecomastia with decreased nipple pain and tenderness ( Figure 2 ). Four months after starting treatment with dasatinib, the patient was also evaluated for CML: bone marrow analysis showed complete cytogenetic response and undetectable bcr-abl transcript by real-time PCR. Secondly, why did our patient develop gynecomastia during dasatinib treatment and not when taking imatinib? Thirdly, should we treat CML patients with gynecomastia triggered by tyrosine kinase inhibitors?
Our patient had reduced levels of testosterone and free testosterone besides elevated 17-hydroxyprogesterone (17-OHP). The rise in 17-OHP could be attributable to an accumulation of steroid precursors consequential to impairment of key enzymes of the steroidogenic cascade, such as 17,20 Lyase (Cyp 17) or 17 ketosteroid reductase. 5 By inhibiting c-kit and PDGFR, imatinib is likely to reduce the cytoplasmatic availability of Cyp 17 and testosterone production. 6 Reduced Figure 1 Bilateral gynecomastia, with enlargement of soft and elastic tissue concentric to the nipple area, 2 months after dasatinib treatment
Letters to the Editor levels of testosterone seem to be responsible for gynecomastia. Dasatinib is also a potent inhibitor of Src kinases. Recent reports have highlighted the importance of these proteins in transducing testosterone action in Sertoli cells. 4 However, the relationship between Src kinase inhibition and gynecomastia is unclear and further studies will be required to uncover the complex interactions between Sertoli and Leydig's cells in the downregulation of testosterone activity, secondary to Src inhibition. Because gynecomastia is the expression of a complex clinical condition, other individual factors may also play a role, considering, for example, that 50% of men in their 70s have low free testosterone concentrations.
In a report by Gambacorti-Passerini et al. 5 only 18% of CML patients developed gynecomastia after 5-13 months of treatment with imatinib. Interestingly, these authors found a significant correlation between the treatment dose (400 mg versus 4600-800 mg) and the hormonal abnormalities. It is possible that a 'threshold dose' of the drug is necessary to block steroidogenic enzyme activities. This would explain why our patient did not develop gynecomastia during treatment with imatinib, 400 mg daily, but instead developed this side effect, combined with a reduction of free-testosterone, when shifted to therapy with dasatinib. In fact, previous in vitro studies have shown that dasatinib exerts a more potent inhibitory action on c-kit and PDGFR-b: IC50 values of 5 and 28 nM, respectively, compared to imatinib with IC50 values of 100 and 30 nM, respectively. 7 The fact that gynecomastia is a rare event during dasatinib therapy may be because, compared to imatinib, this drug is still under-used.
Recent studies have shown a clear relationship between androgen deprivation and vasomotor symptoms, osteoporosis, anemia, gynecomastia, depression, cognitive decline and sexual dysfunction besides endocrine and metabolic disarray, resulting in increased rates of diabetes and myocardial infarction. 8 Therefore, patients with drug-induced gynecomastia should also be treated for the underlying hormonal abnormalities, which often represent the major clinical problem.
Repeated three-monthly cycles of tamoxifen are a therapeutic option currently available for gynecomastia. This drug has little or no side effects and is capable of interrupting secondary androgen deprivation in patients. 8 In vitro studies indicate that dasatinib is a substrate and inhibitor of cytochrome P450 isoenzyme CYP3A4. Consequently, drugs that are metabolized primarily by or modulate the activity of CYP3A4 have the potential to interact with dasatinib. As tamoxifen is a substrate of CYP3A4, the concomitant employment of the two drugs is likely to enhance the effects of tamoxifen. Alternative treatments for gynecomastia include radiotherapy to the breast, subareolar mastectomy, aromatase inhibitors and danazole.
The growing availability of new and more potent tyrosine kinase inhibitor molecules makes it mandatory for the clinician to be aware of the possible inhibitory effects of these molecules against other members of the tyrosine kinase family. We strongly recommend assessment of the hormonal status of male CML patients, before and during treatment, so that corrective measures can be introduced to compensate for the eventual presence of testosterone deprivation. Cattedra di Genetica Medica, PO 'R Binaghi', Università di Cagliari, Cagliari, Italy E-mail: gcaocci@alice.it Table 1 Hormonal status of the patient before and after 3 months of dasatinib treatment 
